Jubilant Profits Spurred By Foreign Business
This article was originally published in PharmAsia News
Executive Summary
Buoyed chiefly by earnings from its foreign businesses, India's pharmaceuticals and chemicals major Jubilant Organosys reported a net profit of 4 billion rupees ($98 million) for the year ending March 31
You may also be interested in...
Indian Companies Look To Emphasize Drug Technology Advantages Rather Than Cost Savings With MNCs
FRANKFURT, Germany - Indian drug companies are sharpening their focus on technology to take contract manufacturing and service capabilities to a stage where multinational companies will look to partner for reasons other than cost savings
Indian Companies Look To Emphasize Drug Technology Advantages Rather Than Cost Savings With MNCs
FRANKFURT, Germany - Indian drug companies are sharpening their focus on technology to take contract manufacturing and service capabilities to a stage where multinational companies will look to partner for reasons other than cost savings
PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant
NEW DELHI - India's fifth largest generic drug firm Lupin wants to buy other drug formulation companies in the U.S., Latin America, Southeast Asia and the Middle East this year to expand its presence overseas its chairman said after announcing a sharp, but expected, drop in earnings for the fourth quarter ended March 31